Skip to content

Efficacy of Point Of Service Testing in MBC

Efficacy of Point Of Service Testing in Metastatic Breast Cancer

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03983577
Acronym
EPOST MBC
Enrollment
100
Registered
2019-06-12
Start date
2019-06-11
Completion date
2025-08-31
Last updated
2023-09-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Metastatic Cancer

Keywords

genetic counseling

Brief summary

This study will assess the efficacy of an innovative point of service cancer genetics counseling delivery model for metastatic breast cancer (MBC) patients whom have received a referral for hereditary cancer genetic counseling and testing.

Interventions

OTHERPoint of service delivery model

Participants will receive the pre-test survey, followed by the combined provider/telehealth genetic counseling education video for genetic testing. Afterwards, the participants will receive a post-test and patient satisfaction survey.

Sponsors

University of Kansas Medical Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Ability of participant OR Legally Authorized Representative (LAR) to understand this study, and participant or LAR willingness to sign a written informed consent. * Able to speak and read in the English language. * Have a diagnosis of human epidermal growth factor receptor 2 (HER2) negative metastatic breast cancer. * Participants must be enrolled in the parent registry study.

Exclusion criteria

* Genetic testing for a breast cancer gene (BRCA) BRCA1 and BRCA2 mutation completed after 2013 or any BRCA 1 and BRCA2 testing with large rearrangement testing. Prior genetic counseling is allowed. * Psychiatric illness/social situations that would limit compliance with study requirements.

Design outcomes

Primary

MeasureTime frameDescription
Proportion of patients/participants that undergo hereditary cancer genetic testing after the telehealth intervention.24 monthsDefined as the number of participants who opt to undergo hereditary cancer genetic testing as a percentage of the total number of participants enrolled.

Secondary

MeasureTime frameDescription
Overall participant satisfaction24 monthsPatient satisfaction will be assessed with an adapted Genetic Counseling Satisfaction Scale (aGCSS). Each item is scored from 1- 5, with 1 being strongly disagree and 5 being agree strongly. The scores are added then divided by 5 to give a mean score.
Clinical decisional conflict score24 monthsDecisional conflict will be assessed using the Decisional Conflict Scale (Sure Test Version). The 4 items are summed. Scores range from 0 (extremely high decisional conflict) to 4 (no decisional conflict). A score of less than or equal to 3 indicates decisional conflict.
Overall participant anxiety24 monthsParticipant anxiety will be assessed with the Hospital Anxiety and Depression Scale (HADS-Anxiety scale). Each item is scored between 0- 3 with a total score between 0- 21 possible. Scores of 0-7 indicates normal; scores of 8-10 indicates borderline abnormal; scores of 11-21 indicates abnormal.

Countries

United States

Contacts

Primary ContactCT Nurse Navigator
ctnursenav@kumc.edu913-945-7552

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026